There are currently 632 clinical trials in Louisville, Kentucky looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Louisville, Jewish Hospital, Norton Cancer Institute and Saints Mary and Elizabeth Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects
NCT03669614
Recruiting
This is a Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of AR-501 (gallium citrate) solution, administered via inhalation, in healthy adult and P. aeruginosa infected cystic fibrosis (CF) subjects. Phase 1 of the study in HV subjects will consist of a single-ascending-dose (SAD) cohort, followed by the HV multiple-ascending-dose (MAD) cohort. Phase 2a of the study in CF subjects will consist of a MAD study design. The study will evaluate the safety and pharmaco... Read More
Gender:
All
Ages:
Between 18 years and 49 years
Trial Updated:
03/07/2023
Locations: Research Site, Louisville, Kentucky
Conditions: Cystic Fibrosis
Register for Updates
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
NCT03412643
Recruiting
This is a prospective, single arm, open label, multicenter interventional study designed to evaluate the efficacy of neoadjuvant chemotherapy with anti-HER2 antibodies in patients with HER2-negative invasive breast cancer who have abnormal HER2 signaling activity determined by the Celcuity CELx HER2 Signaling Function (HSF) testing.
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/03/2023
Locations: University of Louisville JG Brown Cancer Center, Louisville, Kentucky
Conditions: HER2-negative Breast Cancer
Register for Updates
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
NCT03787602
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel Cell Carcinoma (MCC) who have failed treatment with at least one anti-PD-1 or anti-PD-L1 immunotherapy or in combination with avelumab in MCC patients who are anti-PD-1 or anti-PD-L1 treatment naïve. Inhibition of MDM2 is a novel mechanism of action in MCC.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/28/2023
Locations: Norton Healthcare, Louisville, Kentucky
Conditions: Merkel Cell Carcinoma
Register for Updates
A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors
NCT04452955
Recruiting
This is a multi-center, Phase 2, open-label, single dose level study of PRL3-zumab monotherapy in patients with unresectable or metastatic solid tumor.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/28/2023
Locations: Norton Healthcare, Louisville, Kentucky
Conditions: Solid Tumor
Register for Updates
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors
NCT04768868
Recruiting
A Phase 1 Dose Escalation and Expansion Study of IMP7068 Monotherapy in Advanced Solid Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2023
Locations: Norton Cancer Institute, Louisville, Kentucky
Conditions: Advanced Solid Tumors
Register for Updates
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
NCT01838512
Recruiting
The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2023
Locations: Local Institute, Louisville, Kentucky +1 locations
Conditions: Multiple Myeloma
Register for Updates
Metal Panel Allergen Patch Test Study
NCT04500834
Recruiting
Metal allergen patch test study.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
02/10/2023
Locations: DS Research, Louisville, Kentucky
Conditions: Atopic Dermatitis Eczema
Register for Updates
Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma
NCT05700955
Recruiting
The primary purpose of this study is to test the safety of Pembrolizumab and Temozolomide in treating recurrent glioblastoma and to characterize the effect of this treatment on the participants tumor and immune system..
Gender:
All
Ages:
18 years and above
Trial Updated:
01/18/2023
Locations: James Graham Brown Cancer Ctr., Louisville, Kentucky
Conditions: Glioblastoma
Register for Updates
The PATH Home Trial: A Comparative Effectiveness Study of Peripartum Opioid Use Disorder in Rural Kentucky
NCT03725332
Recruiting
Perinatal opioid use disorder (OUD) is a major health concern in the U.S. with significant impact on mothers, infants, and communities. Investigators at the University of Kentucky/UK HealthCare (UK) have developed a comprehensive clinical care model for perinatal OUD (known as UK-PATHways) that has demonstrated success in maternal and neonatal outcomes. The overreaching goals of the proposed project are to: 1) expand the reach of this successful clinical program, 2) to reduce the impact of perin... Read More
Gender:
Female
Ages:
Between 18 years and 55 years
Trial Updated:
12/01/2022
Locations: OB/GYN & Women's Health University of Louisville, Louisville, Kentucky
Conditions: Neonatal Abstinence Syndrome
Register for Updates
A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
NCT03899636
Recruiting
Subjects will be offered the opportunity to participate in a randomized, controlled, 2-arm, unblinded multicenter trial (RCT). There will be 2 study arms: the control arm receiving chemotherapy with the modified FOLFIRINOX regimen alone; and the irreversible electroporation (IRE) arm, receiving chemotherapy with the modified FOLFIRINOX regimen followed by IRE with the NanoKnife System using either an open or a percutaneous approach. All subjects will be treated with the modified FOLFIRINOX regim... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/23/2022
Locations: Norton Healthcare, Louisville, Kentucky
Conditions: Stage III Pancreatic Cancer
Register for Updates
CERENOVUS Neurothrombectomy Devices Registry
NCT05591183
Recruiting
A post-market registry evaluating the EmboTrap® Revascularization Device and CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter in acute ischemic stroke patients with confirmed intracranial large vessel occlusion.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/19/2022
Locations: Norton Healthcare, Louisville, Kentucky
Conditions: Cerebral Stroke
Register for Updates
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
NCT03926624
Recruiting
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), dependin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/18/2022
Locations: Norton Cancer Institute, Louisville, Kentucky
Conditions: Leukemia, Myeloid, Acute
Register for Updates